PMV
PMV Do and dare company
mute

PMV is a do and dare company that is shaping the future of the Flemish economy.

PMV provides finance for promising businesses, from their very start, through their various growth stages and even on to operating internationally.

Working with and for the government and other partners, PMV implements projects that are important for prosperity and wellbeing in Flanders.

PMV coordinates the investment funds of the European Fund for Strategic Investments (EFSI) in Flanders

PMV is the contact point for every enquire for the Juncker Plan, officially the "European Fund for Strategic Investments" (EFSI).

More info

News

01
/02

Confo Therapeutics: 1,6 M. Euros for new fibrosis treatments and 0,97 M Euros for expanding Confo technology

Confo Therapeutics, an emerging drug discovery company, today announced that it has received a €1.6 million grant from VLAIO (Flanders Innovation & Entrepreneurship). Confo Therapeutics will use the grant, which has a duration of 2 years and which will mostly be allocated to the Company’s Drug Discovery Center in Gent, to discover new GPCR agonist compounds for the treatment of fibrosis. Last month, through its Target Discovery Center in Brussels, the Company was also awarded a €0.97 million grant from Innoviris, the Brussels Institute for the encouragement of scientific research and innovation, to further broaden the applicability of its proprietary Confo® technology.

portfolio

Amakem

Amakem
Testimonial: 
Amakem is een Limburgs farmabedrijf dat innovatieve behandelingen ontwikkelt tegen oogziektes. Hun belangrijkste programma is het onderzoek van kinase-inhibitoren, of middelen die eiwitten helpen hun werk als antistoffen beter te doen.

Multiplicom

Multiplicom
Testimonial: 
Multiplicom is specialist in moleculaire diagnostiek om te bepalen of iemand een verhoogd risico heeft om een ziekte te ontwikkelen, om genetische defecten op te sporen en om dokters effectieve medicijnen te laten voorschrijven.

Formac

Formac Pharmaceuticals
Testimonial: 
Formac is een spin-off van de Universiteit Leuven die zich focust op de formulering van slechte wateroplosbare geneesmiddelen.

Apitope

Apitope
Testimonial: 
Apitope is een Europees biotechbedrijf gericht op het onderzoek en ontwikkeling van revolutionaire ziektetherapieën voor auto-immuunziekten en allergieën, zoals multiple sclerose, de ziekte van Graves en Factor VIII.